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Abstract
Background: Achilles tendon (AT) pathologies, particularly Achilles enthesitis, are common in inflammatory arthritis
(IA). Although there are various non-pharmacological interventions and injection therapies available, it is unknown if
these interventions are effective for people with IA, as this population is often excluded from studies investigating
the management of AT pathologies. This study aimed to identify and critically appraise the evidence for non-
pharmacological interventions and corticosteroid injections in the management of AT pathology in those with IA.
Methods: All studies which met the inclusion criteria (AT interventions in adults with a working clinical diagnosis of
IA, English language) were identified from the following databases: Medline, Embase, CINAHL and the Cochrane
Library. The search strategies used the search terms ‘spondyloarthropathies’, ‘inflammatory arthritis’, ‘achilles tendon’,
‘physical therapy’, ‘conservative management’, ‘injections’, and related synonyms. Studies included were quantitative
longitudinal design, such as randomised controlled trials, pseudo randomised and non-randomised experimental
studies, observational studies, cohort studies, and case control studies. All outcome measures were investigated,
quality assessment to determine internal and external validity of included studies was undertaken, and qualitative
data synthesis was conducted.
Results: Of the 10,911 articles identified in the search strategy, only two studies that investigated the efficacy of
corticosteroid injections for the management of the AT in IA met the inclusion criteria, and no studies were
identified for non-pharmacological interventions. Both injection studies had low quality rating for internal and
external validity, and thus overall validity. The included studies only investigated two outcome domains: pain and
ultrasound (US) (B Mode and Doppler) identified abnormalities and vascularity in the AT. There is weak evidence
suggesting a short-term improvement (6–12 weeks) in pain and for the reduction in some abnormal US (B-Mode
and Doppler) detectable features (entheseal thickness, bursitis, and entheseal vascularity) at the AT and surrounding
structures post-corticosteroid injection.
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Conclusion: Weak evidence is available regarding the efficacy of corticosteroid injections in reducing pain and
inconclusive evidence for the improvement of abnormal US detectable features. No studies were identified for non-
pharmacological interventions. It is evident from the lack of relevant literature that there is an urgent need for more
studies assessing non-pharmacological interventions for the AT in people with IA.
Keywords: Achilles tendon, Inflammatory arthritis, Corticosteroid injection, Non-pharmacological interventions,
Ultrasound
Background
Inflammatory Arthritis (IA) refers to a group of condi-
tions including rheumatoid arthritis (RA), ankylosing
spondylitis (AS), psoriatic arthritis (PsA), and other
spondyloarthropathies (SpAs) [1]. These conditions are
progressive and characterised by joint destruction, pain,
and eventually lead to decreased function [2].
IA has been shown to have a profound impact at both
an individual level (negative impact on quality of life of
those afflicted) and at a societal level (medical expenditure
and work disability) [1–3]. Enthesitis (inflammation oc-
curring at the attachment site of tendons and ligaments to
bone) is regarded to be a hallmark feature of the SpAs [3]
and a known predilection to the insertion of the Achilles
tendon has been reported in the literature [4]. The preva-
lence of Achilles enthesitis in IA, in particular SpAs, is
much higher than the general population [5, 6]. Anecdotal
evidence suggests that enthesitis in the SpAs may be
largely unresponsive to standard pharmacological regi-
mens, with treatment guidelines not recommending con-
ventional disease-modifying anti-rheumatic drugs (DMAR
Ds) due to reported failed efficacy on peripheral enthesitis
[7]. The use of biological drug therapies has been de-
scribed in the literature for those with NSAID-refractory
persistent heel enthesitis [8]. However, there is evidence
of the progression of pain and disability even when low
disease activity has been achieved with the use of bio-
logical drug therapies [9].
An association between enthesitis, and the presence of
higher disease activity, increased fatigue, worse func-
tional status, reduced disease duration, and body mass
index was reported in patients with AS [10]. In contrast
to the accepted view that general chronic AT patholo-
gies are primarily degenerative in nature in non IA pop-
ulations, the involvement of a greater inflammatory
component in those with IA has been acknowledged
[11]. This highlights the need for targeted therapies to
address both inflammatory and biomechanical features
affecting the AT, as proposed by Woodburn et al. [12]
for management of rheumatoid arthritis in patients with
low, moderate and high disease activity.
Currently, high quality reviews that can be applied in
clinical practice for the management of AT are unavail-
able. The available Cochrane review by MacLauchlan
and Handoll [13] was withdrawn from the Cochrane
Database due to lack of recency and the need for updat-
ing, and the Cochrane review protocol developed by
Wilson et al. [14] in 2011 was subsequently withdrawn
due to lack of progress. Recent systematic reviews pro-
posing management options for the AT have been pub-
lished, and include many conservative interventions and
injection therapies [15–17]. Physical therapies, such as
progressive heavy load eccentric exercises, gained popu-
larity from the Alfredson’s protocol, and have shown
promising efficacy in reducing pain in recent literature
[16, 18]. Extracorpeal shockwave therapy (ESWT) has
also been reported as being as effective as eccentric exer-
cises [16]. Other conservative management options in-
clude orthoses, splints, low level laser therapy, and
microcurrent therapy. However, these have not been
proven to be as effective as eccentric exercises in studies
[15, 16, 19]. Corticosteroids injections are powerful
anti–inflammatories, and can be useful in patients that
have previously experienced adverse reactions to non-
steroidal anti-inflammatory drugs (NSAIDs) [20]. These
are injected locally at the AT to decrease inflammation
[17]. Although the mechanism through which corticoste-
roids have an effect is unknown, there is evidence to
suggest corticosteroids can be effective in chronic tendi-
nopathy at relieving pain, reducing swelling and inflam-
mation [11, 17]. However, a risk of potential adverse
effects, such as local infection, bleeding, swelling, and
tendon rupture, is associated with corticosteroid injec-
tions. The potential adverse effects of the tendon itself
are local bleeding and weakening of the tendon [17].
Although enthesitis and inflammatory AT pathologies
are a hallmark of IA, those with IA are excluded from
studies focused on the management of AT pathologies.
Consequently, it is currently unknown if treatments for
AT pathologies are safe and effective for people with IA.
This is an important consideration as there is increased
risk of adverse events due to immunosuppression and
studies have shown different pathological processes at
the AT for people with and without IA. Therefore, the
aim of this review was to identify and critically appraise
the evidence for the effectiveness of non-
pharmacological interventions and corticosteroid injec-
tions for the management of the AT in people with IA.
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Methods
Search strategy
A detailed electronic database search of the literature
was performed on August 3rd, 2020 using the following
databases: Medline, Embase, CINAHL, and the
Cochrane Library. Reference lists of eligible studies were
hand searched by the reviewers (SM and KH) to identify
any relevant studies that were not identified through the
initial electronic database search. The following search
terms ‘spondyloarthropathies’, ‘inflammatory arthritis’,
‘achilles tendon’, ‘physical therapy’, ‘conservative man-
agement’, ‘injections’, and related synonyms were used
to develop a comprehensive pragmatic literature search
strategy. Standard MeSH or medical headings and
appropriate keywords were utilised where appropriate
according to each database. Boolean operators (such as
‘OR’, “AND’, and ‘*’) were used as appropriate. The full
search strategies are available in Additional File 1.
Study inclusion criteria
Studies included were quantitative longitudinal study de-
signs, such as randomised controlled trials (RCTs),
pseudo randomised and non-randomised experimental
studies, cohort studies, and case control studies. Single
case studies were excluded. Full text studies published
only in the English language were included due to lan-
guage barriers of the independent reviewers. There were
no limitations on the year of publication. Studies report-
ing participants aged ≥18 years with a working diagnosis
of IA made by a rheumatologist, and AT pathology were
included. Studies investigating non-pharmacological in-
terventions (such as orthoses and physical therapy) and/
or site-specific corticosteroid injections were selected for
further analysis. Limitations were not placed on which
qualified health professional prescribed and/or adminis-
tered the non-pharmacological interventions or cortico-
steroid injections at the AT. All outcome measures were
selected for further analysis. Studies were excluded if
they were not an intervention study or focused solely on
pharmacological treatments, such as biologic drugs as a
primary treatment.
Study selection
All titles and abstracts of the studies found electronically
and through reference list reviews were cross-referenced,
and any duplicates were removed. Two reviewers (SM
and KH) independently screened the title and abstracts
of the studies for information fulfilling the eligibility cri-
teria as described above. Any discrepancies in opinions
were resolved through discussion. Full text articles were
retrieved from the selected abstracts and compared to
the inclusion criteria. Two reviewers (SM and KH) inde-
pendently screened the full text articles to determine if
they met the inclusion criteria. Any discrepancies were
resolved through discussion.
Quality assessment
The quality of the studies was assessed using criteria that
assessed the internal validity (i.e. how well the study was
conducted, including method errors or risk of bias) and
external validity (i.e. generalisability of results to the
wider population of people with IA and affected AT).
The quality assessment criteria used was adapted from
the Cochrane Collaboration tool [21] as previously re-
ported by Hennessy et al. [22]. It included internal valid-
ity criteria of sequence generation and allocation
concealment, blinding of participants, personnel and
outcome assessors, incomplete outcome data, selective
reporting and statistical issues, and interventions. Exter-
nal validity criterion assessed the representativeness of
the sample population to the general population with IA
and affected AT and the restrictiveness of the inclusion
and exclusion criteria [21, 22]. Quality assessment was
conducted by two independent reviewers (SM and KH).
Any disagreements between the two reviewers were re-
solved through discussion. For a high quality rating, all
applicable domains had to be scored as high quality. Any
study with ≥1 domain scoring low quality resulted in an
overall low quality rating for the study. This quality rat-
ing was agreed upon by the co-authors a priori, and has
been used in previous systematic reviews [22, 23].
Data extraction/ evidence grading
For outcome measures, random-effects model meta-
analyses would have been conducted if multiple RCTs
had been available. As multiple RCTs were not available,
qualitative data synthesis was conducted. An evidence
rating was assigned to the extracted data that was ana-
lysed and synthesised. Once the studies were rated for
quality, they were grouped according to intervention and
associated outcome measures, and evidence rating were
assigned according to the criteria adapted from Ariens
et al. [24] (Table 1). The interpretations of findings were
based on combining the qualitative data synthesis and
the evidence grading system.
Results
Using the detailed search strategy, a total of 10,909 arti-
cles were retrieved from Medline, Embase, CINAHL and
Cochrane Library. Two articles were also identified
through reference list reviews. Figure 1 outlines the
flowchart displaying how the relevant studies were found
[25]. The inclusion criteria were met by two studies (de-
scribed in Table 2), which were both observational stud-
ies that assessed the effects of injecting corticosteroid
around the site of the AT [26, 27]. No studies assessing
non-pharmacological interventions (such as orthoses
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and physical therapy) for the AT in patients with IA
were found.
The study by Huang et al. [26] compared the efficacy
of ultrasound (US) guided injections of etanercept and
betamethasone (corticosteroid) when injected into the
entheses of patients with AS and refractory Achilles
enthesitis. The study by Srivastava & Aggarwal [27] in-
vestigated the efficacy of US guided corticosteroid
(methylprednisolone) injections at Achilles enthesis in
patients with SpAs. In the case of Huang et al. [26], only
the corticosteroid injection reported outcomes for the
seven patients who were injected with betamethasone
were extracted, as the inclusion criteria of our systematic
review did not include biologic pharmacological agents
such as etanercept.
The sample size in both studies were small, lacked
a robust sample size calculation, and had a male gen-
der predominance (M:F = 6:1 [26], M:F = 8:1 [27]),
thus making it hard to deduce any potential gender
specific differences in results. Heterogeneity in the
Table 1 - Evidence Rating Criteria [24]
Level Criteria
Strong At least 2 studies of high quality with consistent findings (agreement of > 75% of studies)
Moderate 1 high quality study and at least 2 low-quality studies with consistent findings (agreement of > 75% of studies)
Weak At least 2 low-quality studies with consistent findings
(agreement of > 75% of studies)
Inconclusive Insufficient and/or conflicting studies
Fig. 1 Search flowchart for non-pharmacological interventions and corticosteroid injections for the Achilles tendon in inflammatory arthritis
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type of IA existed across the two studies, with Huang
et al. [26] solely including patients with AS, whereas
Srivastava & Aggarwal [27] represented subcategories
of SpA, including those diagnosed with AS, juvenile
SpA, PsA, inflammatory bowel disease-associated arth-
ritis, and undifferentiated SpA.
The two studies were rated as having overall low in-
ternal and external validity during quality assessment
(Table 3). Two outcome domains were identified: pain
and US (B Mode and Doppler) identified abnormalities
and vascularity in the AT. Considerable variation in the
study duration and timing of outcomes assessments was
noted in the two studies. Huang et al. [26] measured
clinical parameters at baseline with follow up outcomes
measures reported at 2, 4, 8 and 12 weeks. Srivastava &
Aggarwal [27] had a shorter follow-up duration with the
assessment of clinical parameters only at baseline and 6
weeks. Additionally, Huang et al. [26] investigated
patients that had unilateral AT enthesitis (only one foot
investigated), whereas Srivastava & Aggarwal [27] inves-
tigated symptomatic AT, which meant an individual par-
ticipant may have had both ATs assessed if they were
symptomatic. The loss to follow up varied across the
studies, with no loss to follow up reported by Huang
et al. [26], but considerable attrition (38% of study par-
ticipants) was reported by Srivastava & Aggarwal [27],
with a failure of the authors to offer any explanatory
cause for the high levels of attrition in the study.
Due to the lack of RCTs and/or sufficient studies/data
for analysis, meta-analyses could not be conducted, as was
the original intention of this work. A qualitative synthesis
of the results is outlined below and described in Table 4.
Pain
Both studies used a visual analogue scale (VAS) as an
outcome measure for pain. Neither of the two studies
Table 2 – Description of Included Studies
Author, year Study
Type





Huang et al. [26] OBS AS patients with unilateral
refractory AT enthesitis
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OBS Observational study, AT Achilles tendon, US Ultrasound, M:F Male:Female ratio,
AS Ankylosing spondylitis, SpA Spondyloarthropathies, JSpA Juvenile Spondyloarthropathy, PsA Psoriatic Arthritis,
IBDA Inflammatory Bowel Disease-associated Arthritis, USpA Undifferentiated Spondyloarthropathy.








































N/A N/A Yes No No No Low Low
● Same checklist used for all study designs but N/A for domains 1 and 2 for study designs other than RCT
● N/A Not applicable
3 domains for Internal Validity
YES for all of the domains = HIGH QUALITY
NO for any domain = LOW QUALITY
1 domain for External Validity
YES for domain = HIGH QUALITY
NO for domain = LOW QUALITY
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clarified the nominal scale used for the VAS. The pain
was reported to be reduced in both observational studies
[26, 27]. Huang et al. [26] only included patients that
had a VAS score > 4.0 in the affected heel. The baseline
VAS before betamethasone was injected was 5.3 ± 0.7
(mean ± SD), which reduced to 1.5 ± 0.8 during follow-
up at week 12. However, it should be noted that the
VAS reduced at week 2 (0.8 ± 1.0) and week 4 follow-up
(0.5 ± 0.6) from baseline, but then increased for the next
two follow-ups at week 8 and week 12. Overall, the VAS
remained reduced in comparison to baseline measures
[26]. Srivastava & Aggarwal found patients injected with
methylprednisolone at local site of AT reported a VAS
mean score of 7 with a range of 4–10 prior to injection,
and a mean score of 3 with a range of 0–7 6 weeks post
injection [27]. According to the evidence rating criteria
by Ariens et al. [24], it can be concluded that there is
weak evidence suggesting corticosteroid injections at the
AT may reduce pain in the short term (6–12 weeks) as
both studies reported consistent findings.
Ultrasound evaluation (B-mode and Doppler)
Both Huang et al. [26] and Srivastava & Aggarwal [27]
evaluated the Achilles enthesis and surrounding struc-
tures with B-mode US imaging and Doppler US at base-
line and at follow-up visits. B-Mode US Imaging
evaluated morphological changes and Doppler US
assessed vascularisation at the site of AT. Both studies
reported a small reduction in entheseal thickness and
the presence of retrocalcaneal bursitis [26, 27]. Srivas-
tava & Aggarwal [27] reported a reduction of entheseal
thickness from 6.9 mm to 6.1 mm and a reduction in
bursitis (n) from 26 at baseline to 15 at 6 week follow-
up. Huang et al. [26] reported reduction of entheseal
thickness from 7.6 mm to 6.2 mm and a reduction in
bursitis (n) from 7 at baseline to 3 at 12 week follow-up.
The values for bursitis and entheseal thickness reduced
initially and remained the same from four week follow-
up to twelve week follow-up [26]. No changes in the
number of bone erosions and enthesophytes measured
with B-mode US from baseline to follow-up were re-
ported in both studies [26, 27]. This result is not
unexpected due to the irreversible nature of these fea-
tures. Srivastava & Aggarwal [27] also reported reduc-
tions in entheseal hypoechogenicity (n) from 27 to 19
and peritendinous oedema (n) from 17 to 5. Doppler US
examination was undertaken in both studies to assess
vascularity at the AT at baseline and follow-up. Both
studies utilised different grading systems to measure vas-
cularity (Table 5). The two studies reported a reduction
in entheseal vascularity at follow-up. Huang et al. [26]
reported a reduction in the number of highest grade
from 2 to 0, and Srivastava & Aggarwal [27] reported a
reduction in mean grade from 2 to 0. Srivastava &
Aggarwal [27] also reported a reduction in retrocalcaneal
bursa vascularity.
Overall, there is weak evidence to suggest that US
guided corticosteroid injections can improve some of the
B mode and Doppler US detected features at the AT in
the short term (6–12 weeks). There is weak evidence to
suggest an improvement in entheseal thickness (B
Mode), bursitis (B Mode), and entheseal vascularity
(Doppler) as both studies reported consistent findings.
Weak evidence is also present to indicate no improve-
ment in bone erosion and enthesophyte formation was
observed in both studies following US guided cortico-
steroid injections. There is inconclusive evidence regard-
ing entheseal hypoechogenecity (B Mode), peritendinous
oedema (B Mode), and bursal vascularity (Doppler), as
these features were only investigated in one study [27].
Discussion
The aim of this study was to determine the effectiveness
of non-pharmacological and corticosteroid injections in
the management of the AT in people with IA. Only two
studies met the inclusion criteria. These two studies in-
vestigated the effectiveness of corticosteroid injection
therapy. No other relevant studies investigating the use
of non-pharmacological interventions in this population
were identified. A weak level of evidence was the highest
possible irrespective of study quality, which in this case
were low quality observational studies. To that end,
weak levels of evidence were found for corticosteroid in-
jections decreasing pain and some US (B-mode and
Table 5 – Vascularity Grading System
Vascularity
Grade
Huang et al. [26] Srivastava & Aggarwal [27]
0 N/A No Power Doppler signals
1 No flow signal ≤3 Power Doppler signals
2 Presence of separate dot signals or short linear signals > 3 Power Doppler signals occupying
< 50% of the lesion
3 Presence of clearly discernible vascularity with either many small vessels or several long
vessels with or without visible branching though involving less than half of the entheses
Power Doppler signals occupying >
50% of the lesional area
4 Severe flow signal refers to the presence of vessels involving more than half of the entheses N/A
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Doppler) detected features, such as bursitis, entheseal
thickness, and entheseal vascularity. All other US detect-
able features were either weak evidence for no improve-
ment, which was not unexpected due to the irreversible
nature of these features, or inconclusive due to a lack of
studies.
The included studies, Huang et al. [26] and Srivastava &
Aggarwal [27], both had low quality for internal and exter-
nal validity, and thus overall low quality. The low quality
ratings for internal validity were primarily attributed to
the domains of selective outcome reporting/statistical is-
sues and interventions. An inadequate sample size was
present in both studies with only seven patients injected
with betamethasone in Huang et al. [26], whilst 27 ATs
(18 patients) were injected with methylprednisolone in
Srivastava & Aggarwal [27]. Additionally, a risk of attrition
bias was observed in the study by Srivastava & Aggarwal
[27]. The inclusion of 40 symptomatic AT entheses (in 19
patients) was initially reported. However, only 27 symp-
tomatic AT entheses (in 18 patients) were reported at 6-
week follow-up [27]. The reason for participant drop-out
was not addressed, and it is possible that some partici-
pants did not return due to adverse events or lack of im-
provement [28]. The interventions domain was also a
concern for both studies, as the systemic management of
participants was not recorded. The impact of systemic
management on the effectiveness of localised pharmaco-
logic intervention should be considered, as any localised
improvements may be due to improvement in global dis-
ease activity rather than the effectiveness of the localised
intervention [2]. Additionally, non-pharmacological inter-
ventions are adjunct management strategies in this popu-
lation, and can have limited effect if global disease activity
is not addressed [29]. Therefore, the pharmacological pro-
file of participants with IA should always be accounted for
when investigating non-pharmacological and localised
pharmacological interventions.
External validity was also a focus of the quality assess-
ment as intervention studies need to have a pragmatic
approach, and be generalised to the wider population,
with the aim to inform clinical practice [30]. Our find-
ings revealed that both included studies lacked external
validity. This was due to the minimal representation of
females in comparison to males in both studies, with a
male to female ratio of 6:1 for Huang et al. [26] and 8:1
for Srivastava & Aggarwal [27], and the lack of represen-
tation of common IA subtypes (such as RA) when IA
collectively was being investigated [27]. Therefore, future
intervention study design should consider population ra-
tios for gender and prevalence of IA subtypes to allow
for greater generalisability to the wider population.
Whilst methodological concerns were found, both stud-
ies did demonstrate that corticosteroid injections may be
an effective localised management strategy for the AT in
this population. However, as the study duration from
baseline to final follow-up was short (6–12 weeks), long-
term efficacy or risks and adverse effects may not have
been fully determined. Additionally, whilst there is
evidence of decrease in pain and some radiographic fea-
tures at the AT, the data reviewed did not give insight
into evidence of improvement provided by corticosteroid
injections in terms of disability and quality of life in
people with IA.
As far as the authors are aware, this is the first system-
atic review to investigate the efficacy of non-
pharmacological interventions and corticosteroid injec-
tions for the management of AT pathologies in people
with IA. The identified studies both addressed site-
specific corticosteroid injections for the management of
the AT in IA. The use of corticosteroid injections for
the AT is still controversial due to inconclusive evidence
regarding their efficacy and potential risks [17]. This is
because corticosteroid injections tend to have short-
term benefits with the potential risk of weakening the
structural integrity of tendons long-term. Repeated in-
jections and possible puncture of the tendon substance
can increase the potential risk of AT rupture [11]. Al-
though evidence is limited, there are reported cases of
AT rupture following corticosteroid injection in healthy
population with AT pathologies [17, 31]. However, it is
unknown if this is due to injection technique or the
agent injected [11, 17, 32]. Notwithstanding, there is also
a risk of tendon rupture in the IA population, when
there is too much active inflammation at the tendon:
either primary inflammation (specifically within the ten-
don) or secondary inflammation (from an adjacent loca-
tion) [33, 34]. Therefore, the greater risk between
administering an injection or not administering an injec-
tion needs to be established, and managed accordingly
[17]. Consequently, the European League Against
Rheumatism (EULAR) advises glucocorticosteroid injec-
tions as an adjunctive therapy for localised disease, such
as enthesitis in PsA [35]. Additionally, risk of rupture
due to injection technique may be mitigated by using US
image guidance when injecting [36]. However, this has
not been firmly proven [11]. Interestingly, both included
studies administered injections under US guidance, and
did not report any cases of AT rupture.
Non-pharmacological interventions for the AT, such as
physical therapy consisting of eccentric exercise and
ESWT, have shown positive results in the symptomatic
management of the AT [16]. Additionally, non-
pharmacological interventions can minimise potential
risks involved with local injections, such as rupture, infec-
tion, skin hypersensitivity, and skin depigmentation [37].
However, no studies investigating non-pharmacological
interventions for the management of the AT in people
with IA were found during our comprehensive search.
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Due to the lack of evidence, there is currently no data
available regarding the efficacy of non-pharmacological in-
terventions in patients with IA. The reason is most likely
due to people with IA being excluded from studies on
management of the AT [17].
Exclusion may be attributed to the pathogenesis of AT
pathology, which may differ between non-IA and IA,
with active inflammation observed through US in pa-
tients with IA [11]. Additionally, systemic medications
(such as biological drugs or DMARDs) that patients may
be taking combined with a disease course of variable na-
ture (for example, flares of disease activity and remis-
sions) could impact the findings. If systemic
management is working effectively with subsequent low
disease activity, it may enhance the efficacy of results.
Conversely, if systemic management is not adequately
controlling disease activity, it could lead to less effica-
cious results for non-pharmacological or localised
pharmacological interventions, and could impact adher-
ence to interventions and study attrition rates [2]. As
such, the impact of pharmacological interventions
should be carefully considered in methodological design
and interpretation of study outcome measures.
Therefore, due to the exclusion of people with IA from
studies investigating AT management, further studies in-
vestigating non-pharmacological interventions for this
population are required. Smolen et al. [38], who made rec-
ommendations for treating SpAs, also highlighted the
need for more research into the management of musculo-
skeletal involvement. They recommended that inactive
disease of musculoskeletal involvement, such as enthesitis,
should be a foremost treatment target to optimise quality
of life for patients. Current guidelines also highlight the
importance of non-pharmacological management in over-
all management of axial SpA [39]. These guidelines also
recommend glucocorticoid injections at the localised site
of musculoskeletal inflammation could be considered to
treat enthesitis despite the lack of evidence [39]. Unfortu-
nately, guidelines with recommendations for the non-
pharmacological management of IA specific conditions
were not found, which further emphasises the need for
more research in this area. It should also be noted that the
potential mechanism of action of glucocorticoids in tendi-
nopathy includes decreased inflammation, inhibition of
cellular proliferation, scarring and adhesion, antiangio-
genic activity, antinociceptive action or some combina-
tions of these factors. The results can be positive in cases
where excessive inflammation is prevalent [40, 41]. This
might explain the positive results from the studies in-
cluded in this systematic review due to high inflammation
from the disease process of IA.
There were a number of limitations to this systematic
review that need to be acknowledged. Language was lim-
ited to English due to language restrictions of the
reviewers. This is generally not advised, but is difficult to
overcome [42]. The number of studies that met the inclu-
sion criteria may have been limited due to this, and the re-
sults of studies excluded based on language could have
impacted on the findings of this systematic review. The
second limitation of the study was that the outcome mea-
sures within each domain were the same even if the
methods of determining these outcomes were different,
such as reduced vascularity in the enthesis, which would
be reduced regardless of the differing grading systems
used by the two studies. The second assumption was that
the vascularity was assumed as being decreased overall,
even if it may have increased between follow-ups. The vas-
cularity grade was still reduced at the final follow-up in
comparison to the baseline grade of vascularity.
The findings of this systematic review highlight the urgent
need for high quality research to be conducted to establish
the efficacy of non-pharmacological interventions and injec-
tion therapies for the AT in people with IA to better guide
those responsible for delivering care. Future research should
consider how study outcomes may be interpreted in the
context of co-interventions, such as pharmacological man-
agement, and variable disease course and progression, and
consider analysis for specific subtypes of IA to allow applic-
ability of results in wider clinical practice.
Conclusion
There is some weak evidence for the efficacy of cortico-
steroid injections in reducing pain and improving some
US detectable features in the AT in people with IA. The
efficacy of non-pharmacological interventions could not
be assessed due to a lack of relevant literature. There is
an urgent need for more research in this field. Future
research should address the efficacy of non-
pharmacological interventions and injection therapies
for the AT within the IA population, specifically ad-
dressing different subtypes of IA. An emphasis should
also be placed on external validity to allow for greater
applicability in clinical practice.
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